<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0155273</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-50201</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject><subj-group><subject>Type 2 diabetes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject><subj-group><subject>Type 2 diabetes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Metabolic disorders</subject><subj-group><subject>Diabetes mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Database searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Cardiovascular procedures</subject><subj-group><subject>Coronary stenting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Stent implantation</subject><subj-group><subject>Coronary stenting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Cardiovascular procedures</subject><subj-group><subject>Angioplasty</subject><subj-group><subject>Coronary angioplasty</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Cardiovascular procedures</subject><subj-group><subject>Revascularization</subject><subj-group><subject>Coronary revascularization</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research design</subject><subj-group><subject>Retrospective studies</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Effect of Pioglitazone in Preventing In-Stent Restenosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Shi-jie</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhong</surname>
<given-names>Zhao-shuang</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Qi</surname>
<given-names>Guo-xian</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shi</surname>
<given-names>Li-ye</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Chen</surname>
<given-names>Ling</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Tian</surname>
<given-names>Wen</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Geriatric Cardiology, First Affiliated Hospital, China Medical University, Shenyang, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Respiratory, Central Hospital, Shenyang Medical College, Shenyang, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Croce</surname>
<given-names>Kevin J.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Harvard Medical School, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: SJZ WT GXQ. Performed the experiments: SJZ LC WT. Analyzed the data: SJZ ZSZ. Contributed reagents/materials/analysis tools: ZSZ LYS. Wrote the paper: SJZ WT.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">dr_wentian@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>5</issue>
<elocation-id>e0155273</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>4</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Zhao et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0155273"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>The benefits of pioglitazone in patients with type 2 diabetes mellitus (T2DM) after percutaneous coronary intervention (PCI) is unclear.</p>
</sec>
<sec id="sec002">
<title>Objectives</title>
<p>To evaluate the effect of pioglitazone on prevention of in-stent restenosis (ISR) in patients with T2DM after PCI.</p>
</sec>
<sec id="sec003">
<title>Methods</title>
<p>All full-text published relevant studies compared the effect of pioglitazone with control group (placebo or no pioglitazone treatment) on ISR in patients with T2DM after PCI were identified by searching the databases including PubMed, EMBASE, Cochrane Library and ISI Web of Science through October 2015. The endpoints were defined as the rate of ISR, late lumen loss, in-stent neointimal volume, target lesion revascularization (TLR) and major adverse cardiac events (MACE).</p>
</sec>
<sec id="sec004">
<title>Results</title>
<p>Six studies (5 RCTs and 1 retrospective study), comprising 503 patients, were included into this meta-analysis. In the pioglitazone group, as compared with the control group, the risk ratio for ISR was 0.48 (I<sup>2</sup> = 14.5%, P = 0.322; 95%CI 0.35 to 0.68, P&lt;0.001), the risk ratio for TLR was 0.58 (I<sup>2</sup> = 6.0%, P = 0.363; 95%CI 0.38 to 0.87, P = 0.009). The result showed there was no association between the use of pioglitazone and the events of MACE (I<sup>2</sup> = 36.7%, P = 0.209; RR 0.56, 95%CI 0.30 to 1.05, P = 0.071). For the considerable heterogeneity, further analysis was not suitable for the endpoints of late lumen loss (I<sup>2</sup> = 81.9%, P&lt;0.001) and neointimal volume (I<sup>2</sup> = 75.9%, P = 0.016).</p>
</sec>
<sec id="sec005">
<title>Conclusions</title>
<p>The treatment of pioglitazone was associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The authors have no support or funding to report.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<page-count count="10"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information file.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec006" sec-type="intro">
<title>Introduction</title>
<p>In-stent restenosis (ISR) is considered as the leading problem after percutaneous coronary intervention (PCI), especially in patients with type 2 diabetes mellitus (T2DM)[<xref ref-type="bibr" rid="pone.0155273.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0155273.ref002">2</xref>]. Thiazolidinediones (TZDs), agonists of the peroxisome proliferation-activated receptor-γ (PPAR-γ), usually used to improve insulin sensitivity and reduce blood glucose levels in diabetic patients, could also inhibit proliferation and migration of vascular smooth muscle cells (VSMCs) and ameliorate inflammation after vascular injury[<xref ref-type="bibr" rid="pone.0155273.ref003">3</xref>–<xref ref-type="bibr" rid="pone.0155273.ref005">5</xref>]. Among the three TZDs, pioglitazone may be the only one which shows beneficial effects on cardiovascular outcomes and appears to be promising in clinical application[<xref ref-type="bibr" rid="pone.0155273.ref006">6</xref>–<xref ref-type="bibr" rid="pone.0155273.ref008">8</xref>]. Previous meta-analysis has suggested that pioglitazone is effective in decreasing ISR and the need for revascularization after bare-metal stents (BMS) implantation in diabetic patients[<xref ref-type="bibr" rid="pone.0155273.ref009">9</xref>]. However, drug-eluting stents (DES) are more widely used in recent years. Diabetes mellitus was also regarded as one of the most powerful clinical predictors of ISR after DES implantation as same as in BMS era[<xref ref-type="bibr" rid="pone.0155273.ref010">10</xref>–<xref ref-type="bibr" rid="pone.0155273.ref012">12</xref>]. A hypothesized independent anti-restenotic effect of pioglitazone in patients with T2DM has not been clearly demonstrated[<xref ref-type="bibr" rid="pone.0155273.ref013">13</xref>]. Thus, we performed this meta-analysis to investigate the effect of pioglitazone on prevention of ISR in patients with T2DM after PCI, with update information both on BMS and DES implantation.</p>
</sec>
<sec id="sec007" sec-type="materials|methods">
<title>Methods</title>
<p>This meta-analysis was conducted according to the PRISMA statement [<xref ref-type="bibr" rid="pone.0155273.ref014">14</xref>], and the PRISMA checklist is provided as <xref ref-type="supplementary-material" rid="pone.0155273.s001">S1 Table</xref>.</p>
<sec id="sec008">
<title>Search Strategy</title>
<p>We searched the databases including PubMed (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed" xlink:type="simple">http://www.ncbi.nlm.nih.gov/pubmed</ext-link>), EMBASE (<ext-link ext-link-type="uri" xlink:href="http://www.embase.com/" xlink:type="simple">http://www.embase.com</ext-link>), Cochrane Library (<ext-link ext-link-type="uri" xlink:href="http://www.cochranelibrary.com/" xlink:type="simple">www.cochranelibrary.com</ext-link>) and ISI Web of Science (<ext-link ext-link-type="uri" xlink:href="http://www.webofknowledge.com/" xlink:type="simple">http://www.webofknowledge.com</ext-link>) for all full-text published relevant studies compared the effect of pioglitazone with control group (placebo or no pioglitazone treatment) in T2DM patients after PCI through October 2015. Search terms included any possible combination of the keywords of ‘‘restenosis”, ‘‘percutaneous coronary intervention or PCI”, ‘‘pioglitazone” and ‘‘diabetes”.</p>
</sec>
<sec id="sec009">
<title>Study selection</title>
<p>Two independent reviewers (S.-J.Z. and L.C.) were involved in the search for potentially eligible studies and in the inclusion process. In case of disagreement, a decision was made under the supervision of the senior author (W.T.). Studies will be included if they met the following criteria: (1) RCT or high quality retrospective study, (2) pioglitazone was administered and compared with control group (placebo or no pioglitazone treatment) for patients who suffered from diabetes and performed PCI, and (3) the studies included at least one of the following interesting outcomes: ISR (defined as stenosis more than 50% at the site of stent), late loss (change in minimum lumen diameter at the stent site from baseline to follow-up), in-stent neointimal volume (neointimal volume/length of stent) measured by intravenous ultrasound (IVUS), target lesion revascularization (TLR) and major adverse cardiac events (MACE, including target vessel revascularization, acute myocardial infarction, cardiac death, etc.).</p>
</sec>
<sec id="sec010">
<title>Data abstraction and quality assessment</title>
<p>For all included studies, we recorded the baseline information of the study, including the number of subjects, patients’ characteristics, interventions in each group, methodology quality of the study, outcomes with ascertained method and length of follow-up. The data were extracted independently by two authors(S.-J.Z. and L.C.) using a pre-designed data extraction form. As before, disagreements will be resolved by discussion and referral to the senior author(W.T.) if necessary.</p>
</sec>
<sec id="sec011">
<title>Statistical analysis</title>
<p>The treatment effect for continuous outcomes are expressed as weighted mean difference (WMD) with 95% confidence intervals (CI) for all studies used the same scale[<xref ref-type="bibr" rid="pone.0155273.ref015">15</xref>]. For dichotomous data, the pooled risk ratios (RRs) would be used. Statistical heterogeneity across the studies was measured by I<sup>2</sup> test, and a fixed-effects (FE) model (Mantel-Haenszel method) would be used if I<sup>2</sup>≤50%. In case of important heterogeneity (50%&lt;I<sup>2</sup>≤75%), further exploration was made if appropriate, including sensitivity analysis and subgroup analysis. If heterogeneity remained significant, a random-effects (RE) model would be used. If there was considerable heterogeneity (I<sup>2</sup>&gt;75%), the data would be regarded as unsuitable for pooling[<xref ref-type="bibr" rid="pone.0155273.ref015">15</xref>]. The publication bias was evaluated by using funnel plots with Begg’s test[<xref ref-type="bibr" rid="pone.0155273.ref016">16</xref>]. A value of P&lt;0.05 indicated statistically significant. All analysis was completed in Stata v12.0 (Stata Corp, College Station, TX,USA) using the metan function.</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Baseline characteristics of included studies</title>
<p>Our search strategy resulted in the initial identification of 125 records. After duplicated removal, 91 studies were left, in which 81 records were further excluded as non-clinical studies, reviews, case reports or irrelevant studies after the title and abstract screening. As a result, a total of 10 studies were left for full-text screening to determine eligibility for analysis.</p>
<p>After full-text screening, 4 studies were removed due to either inappropriate set of experimental group, lack of interested outcome or other reasons[<xref ref-type="bibr" rid="pone.0155273.ref017">17</xref>–<xref ref-type="bibr" rid="pone.0155273.ref020">20</xref>]. Finally, 6 studies (5 RCTs and 1 retrospective study) involved a total of 503 cases, were selected for inclusion in the meta-analysis. A flow chart summarizes the selection process of the studies (<xref ref-type="fig" rid="pone.0155273.g001">Fig 1</xref>), and the detail information of the included studies is provided in <xref ref-type="table" rid="pone.0155273.t001">Table 1</xref>[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>].</p>
<fig id="pone.0155273.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow chart of study selection.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0155273.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.t001</object-id>
<label>Table 1</label> <caption><title>Baseline characteristics of selected studies.</title></caption>
<alternatives>
<graphic id="pone.0155273.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" rowspan="2">Study</th>
<th align="center" rowspan="2">Year</th>
<th align="center" rowspan="2">Study design</th>
<th align="center" rowspan="2">Age(PG/CG)</th>
<th align="center" rowspan="2">Sample size(PG/CG)</th>
<th align="center" rowspan="2">Stent type</th>
<th align="center" colspan="2">Interventions</th>
<th align="center" colspan="2">Outcomes</th>
<th align="center" rowspan="2">Follow-up</th>
</tr>
<tr>
<th align="center">PG</th>
<th align="center">CG</th>
<th align="center">Routine Follow-up</th>
<th align="center">Clinically Driven</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Lee, H et al.[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>]</td>
<td align="center">2013</td>
<td align="center">RCT</td>
<td align="center">60±10/62±9</td>
<td align="center">60/61</td>
<td align="center">DES</td>
<td align="center">pioglitazone, 15 mg/d</td>
<td align="center">placebo</td>
<td align="center">ISR; Late loss; Neointimal volume; MACE</td>
<td align="center">TLR</td>
<td align="center">12 months</td>
</tr>
<tr>
<td align="center">Soon Jun Hong et al.[<xref ref-type="bibr" rid="pone.0155273.ref022">22</xref>]</td>
<td align="center">2011</td>
<td align="center">RCT</td>
<td align="center">64±7/62±8</td>
<td align="center">47/47</td>
<td align="center">DES</td>
<td align="center">pioglitazone, 30 mg/d</td>
<td align="center">placebo</td>
<td align="center">ISR; Late loss; Neointimal volume; MACE</td>
<td align="center">-</td>
<td align="center">8 months</td>
</tr>
<tr>
<td align="center">Takagi, T et al.[<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>]</td>
<td align="center">2009</td>
<td align="center">RCT</td>
<td align="center">64±9/62±10</td>
<td align="center">48/49</td>
<td align="center">BES</td>
<td align="center">pioglitazone, 30 mg/d</td>
<td align="center">placebo</td>
<td align="center">ISR; Late loss; MACE</td>
<td align="center">TLR</td>
<td align="center">6 months</td>
</tr>
<tr>
<td align="center">Yokoyama, J et al.[<xref ref-type="bibr" rid="pone.0155273.ref024">24</xref>]</td>
<td align="center">2007</td>
<td align="center">Retrospective</td>
<td align="center">63±10/64±9</td>
<td align="center">56/37</td>
<td align="center">BES</td>
<td align="center">pioglitazone, 15 mg/d</td>
<td align="center">without pioglitazone</td>
<td align="center">ISR; Late loss</td>
<td align="center">TLR</td>
<td align="center">6 months</td>
</tr>
<tr>
<td align="center">Nishio, K et al.[<xref ref-type="bibr" rid="pone.0155273.ref025">25</xref>]</td>
<td align="center">2006</td>
<td align="center">RCT</td>
<td align="center">66±9/68±10</td>
<td align="center">26/28</td>
<td align="center">BES</td>
<td align="center">pioglitazone, 30 mg/d</td>
<td align="center">without pioglitazone</td>
<td align="center">ISR; Late loss</td>
<td align="center">-</td>
<td align="center">6 months</td>
</tr>
<tr>
<td align="center">Takagi, T et al.[<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>]</td>
<td align="center">2003</td>
<td align="center">RCT</td>
<td align="center">64±10/65±9</td>
<td align="center">23/21</td>
<td align="center">BES</td>
<td align="center">pioglitazone, 30 mg/d</td>
<td align="center">without pioglitazone</td>
<td align="center">ISR; Neointimal volume</td>
<td align="center">TLR</td>
<td align="center">6 months</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>PG = pioglitazone group; CG = control group; DES = drug-eluting stent; BES = bare-metal stent; ISR = in-stent restenosis; TLR = target lesion revascularization; MACE = major adverse cardiac events.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>The quality assessment and publication bias</title>
<p>The assessment of study quality was performed by application of Modified Jadad scale, which is composed of randomization method, double-blinding, withdrawals and dropouts and allocation concealment[<xref ref-type="bibr" rid="pone.0155273.ref027">27</xref>]. The Jadad scores of the studies are summarized in <xref ref-type="table" rid="pone.0155273.t002">Table 2</xref>. The publication bias was assessed by a funnel plot, which was based on the outcome of ISR (<xref ref-type="fig" rid="pone.0155273.g002">Fig 2</xref>), and no publication bias was found (Begg’s test, P = 0.707).</p>
<fig id="pone.0155273.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Funnel plot for the events of ISR.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.g002" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0155273.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.t002</object-id>
<label>Table 2</label> <caption><title>Methodologic quality assessment of selected studies.</title></caption>
<alternatives>
<graphic id="pone.0155273.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Author</th>
<th align="left">Randomization</th>
<th align="left">Randomization method</th>
<th align="left">Blinding</th>
<th align="left">Withdrawals/dropouts</th>
<th align="left">Allocation concealment</th>
<th align="left">Scores</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Lee, H et al.[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>]</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">Unclear</td>
<td align="left">No</td>
<td align="left">Unclear</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Soon Jun Hong et al.[<xref ref-type="bibr" rid="pone.0155273.ref022">22</xref>]</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">single blind</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Takagi, T et al.[<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>]</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">open label</td>
<td align="left">No</td>
<td align="left">Unclear</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">Yokoyama, J et al.[<xref ref-type="bibr" rid="pone.0155273.ref024">24</xref>]</td>
<td align="left">No</td>
<td align="left">No</td>
<td align="left">No</td>
<td align="left">No</td>
<td align="left">No</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">Nishio, K et al.[<xref ref-type="bibr" rid="pone.0155273.ref025">25</xref>]</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">Unclear</td>
<td align="left">No</td>
<td align="left">Unclear</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left">Takagi, T et al.[<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>]</td>
<td align="left">Yes</td>
<td align="left">Unclear</td>
<td align="left">double blind</td>
<td align="left">No</td>
<td align="left">Unclear</td>
<td align="left">4</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec015">
<title>Statistical Analysis Results</title>
<sec id="sec016">
<title>In Stent Restenosis</title>
<p>There was no significant heterogeneity among the six studies[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>] (I<sup>2</sup> = 14.5%, P = 0.322), so the FE model was used. In the six studies, the events of ISR occurred in 41 of 249 patients (16.5%) treated with pioglitazone and in 72 of 227 patients (31.7%) without pioglitazone treatment. The use of pioglitazone was associated with a significant reduction in the events of ISR (RR 0.48, 95% CI 0.35 to 0.68, P&lt;0.001) (<xref ref-type="fig" rid="pone.0155273.g003">Fig 3</xref>).</p>
<fig id="pone.0155273.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.g003</object-id>
<label>Fig 3</label>
<caption>
<title>RR of the events of ISR.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title>Late Loss</title>
<p>The late loss was reported after pioglitazone treatment in the diabetic patients suffered from PCI in 5 studies[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0155273.ref025">25</xref>]. There was considerable heterogeneity among these studies (I<sup>2</sup> = 81.9%, P&lt;0.001). As a result, the data about late loss in the studies were not suitable for further analysis.</p>
</sec>
<sec id="sec018">
<title>Neointimal Volume</title>
<p>The neointimal volume of the target lesion was investigated by IVUS at 1 year follow-up in 3 studies[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0155273.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>]. After pooling the data of the studies, we were not able to perform further analysis for the results of neointimal volume because of the considerable heterogeneity among the studies (I<sup>2</sup> = 75.9%, P = 0.016).</p>
</sec>
<sec id="sec019">
<title>Target Lesion Revascularization</title>
<p>The meta-analysis was performed with FE model for there was no significant heterogeneity among the 4 studies [<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>,<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0155273.ref024">24</xref>,<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>] (I<sup>2</sup> = 6.0%, P = 0.363). Pioglitazone treatment was associated with a significant reduction in the events of TLR (RR 0.58, 95%CI 0.38 to 0.87, P = 0.009) (<xref ref-type="fig" rid="pone.0155273.g004">Fig 4</xref>).</p>
<fig id="pone.0155273.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.g004</object-id>
<label>Fig 4</label>
<caption>
<title>RR of the events of TLR.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec020">
<title>Major Adverse Cardiac Events</title>
<p>The incidence of MACE was reported in three studies[<xref ref-type="bibr" rid="pone.0155273.ref021">21</xref>–<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>], and there was no significant heterogeneity among them (I<sup>2</sup> = 36.7%, P = 0.209). After the application of FE model for the meta-analysis, the result showed there was no association between the treatment of pioglitazone and MACE (RR 0.56, 95%CI 0.30 to 1.05, P = 0.071) (<xref ref-type="fig" rid="pone.0155273.g005">Fig 5</xref>).</p>
<fig id="pone.0155273.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0155273.g005</object-id>
<label>Fig 5</label>
<caption>
<title>RR of the events of MACE.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.g005" xlink:type="simple"/>
</fig>
</sec>
</sec>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Discussion</title>
<p>Inflammation response evoked by stent implantation, which initiates several vascular remodeling processes including neointimal hyperplasia, is crucial contributor to the development of restenosis after PCI[<xref ref-type="bibr" rid="pone.0155273.ref028">28</xref>], especially in patients with T2DM[<xref ref-type="bibr" rid="pone.0155273.ref029">29</xref>]. As anti-diabetic agents involved in insulin sensitivity and lipid metabolism, TZDs can activate PPAR-γ, which is highly expressed in activated macrophages after PCI[<xref ref-type="bibr" rid="pone.0155273.ref030">30</xref>], to exert its anti-inflammatory and anti-proliferative effect in the process of ISR[<xref ref-type="bibr" rid="pone.0155273.ref031">31</xref>–<xref ref-type="bibr" rid="pone.0155273.ref034">34</xref>]. However, among the three TZDs, troglitazone is not approved due to its liver toxicity[<xref ref-type="bibr" rid="pone.0155273.ref008">8</xref>], and rosiglitazone is associated with increased risk of myocardial infarction[<xref ref-type="bibr" rid="pone.0155273.ref006">6</xref>]. So, as the only one which shows beneficial effects on cardiovascular outcomes in TZDs, pioglitazone is considered to be a more promising drug on the prevention of ISR[<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0155273.ref035">35</xref>].</p>
<p>Although the incidence of ISR was markedly reduced since DES have been widely used [<xref ref-type="bibr" rid="pone.0155273.ref036">36</xref>,<xref ref-type="bibr" rid="pone.0155273.ref037">37</xref>], a fairly high rate of ISR (10.1% to 17.6%) after DES implantation still exists in patients with T2DM[<xref ref-type="bibr" rid="pone.0155273.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0155273.ref038">38</xref>], which probably due to the amplified inflammatory response and increased neointimal hyperplasia. Therefore, diabetes is one of the most powerful clinical predictors of ISR after PCI regardless of the kind of stents used[<xref ref-type="bibr" rid="pone.0155273.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0155273.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0155273.ref011">11</xref>,<xref ref-type="bibr" rid="pone.0155273.ref039">39</xref>]. Besides, little data is available about the dosage of pioglitazone that can appropriately prevent ISR after PCI with DES, especially in T2DM patients. Therefore, we made the meta-analysis without selection of the kind of stent and the dosage of pioglitazone, which might mainly account for the considerable heterogeneity of late loss and neointimal volume. Nevertheless, as the results have shown, no statistical heterogeneity was found among the included studies for most endpoints, indicating that the results of the study are convincing in some degree.</p>
<p>This study, comprising 503 T2DM patients, demonstrates that the use of pioglitazone was associated with a reduction in ISR and TLR. Although late loss and neointimal volume were not further analyzed due to the considerable heterogeneity among the studies, the beneficial effects of pioglitazone on these endpoints could not be ignored [<xref ref-type="bibr" rid="pone.0155273.ref022">22</xref>,<xref ref-type="bibr" rid="pone.0155273.ref023">23</xref>,<xref ref-type="bibr" rid="pone.0155273.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0155273.ref026">26</xref>]. The benefits of pioglitazone for T2DM patients could be attributed to its favorable effect on lipid profile[<xref ref-type="bibr" rid="pone.0155273.ref040">40</xref>], attenuation of atherosclerotic plaque inflammation[<xref ref-type="bibr" rid="pone.0155273.ref004">4</xref>] and efflux of cholesterol from macrophages[<xref ref-type="bibr" rid="pone.0155273.ref041">41</xref>]. In this regards, Pioglitazone could be an useful agent on the prevention of ISR [<xref ref-type="bibr" rid="pone.0155273.ref042">42</xref>–<xref ref-type="bibr" rid="pone.0155273.ref044">44</xref>]. However, it is worth noting that no studies, including this meta-analysis, have found that pioglitazone reduces cardiovascular events, even the best available data for pioglitazone from the PROactive trial[<xref ref-type="bibr" rid="pone.0155273.ref045">45</xref>]. For this reason, the results of the study should be interpreted with care and more high quality clinical trials are needed.</p>
<p>Several limitations should be considered in this study. First, for only six studies met our inclusion criteria, the publication bias of the study could not be totally excluded for the low power of funnel plot asymmetry test. Second, the considerable heterogeneity mentioned above, together with the small sample size, lower quality of the RCT trials (Modified Jadad score ranged from 0–4) and the enrollment of one retrospective study, could make the conclusion less convincing. Finally, the lack of subgroup analysis, such as condition of the patients, selection of the stents and the dosage of pioglitazone might also lead to significant bias in the study. Therefore, the results of the study should be interpreted with caution and additional clinical trials are required.</p>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Conclusions</title>
<p>The limited evidence indicates that the treatment of pioglitazone is associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE. However, due to the limitations of the present study, additional high quality RCTs are needed and the results of the study should be interpreted with care.</p>
</sec>
<sec id="sec023">
<title>Supporting Information</title>
<supplementary-material id="pone.0155273.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0155273.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>PRISMA Checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Yan-zhao Lu, Hua Li, Yu-jiao Sun and Li-na Ren for helpful suggestions on the study design and data collection.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0155273.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silva</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Ramee</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>White</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Collins</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Jenkins</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Nunez</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome</article-title>. <source>Am Heart J</source>. <year>1999</year>; <volume>138</volume>: <fpage>446</fpage>–<lpage>455</lpage>. <object-id pub-id-type="pmid">10467194</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Cha</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Chae</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Hur</surname> <given-names>SH</given-names></name>, <etal>et al</etal>. <article-title>Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2010</year>; <volume>76</volume>: <fpage>924</fpage>–<lpage>933</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ccd.22369" xlink:type="simple">10.1002/ccd.22369</ext-link></comment> <object-id pub-id-type="pmid">20815045</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Joner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Farb</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Finn</surname> <given-names>AV</given-names></name>, <name name-style="western"><surname>Acampado</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Burke</surname> <given-names>AP</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2007</year>; <volume>27</volume>: <fpage>182</fpage>–<lpage>189</lpage>. <object-id pub-id-type="pmid">17068283</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kasai</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Miyauchi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yokoyama</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kajimoto</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sumiyoshi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kubota</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting</article-title>. <source>Atherosclerosis</source>. <year>2008</year>; <volume>197</volume>: <fpage>612</fpage>–<lpage>619</lpage>. <object-id pub-id-type="pmid">17950297</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Okura</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takagi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yoshida</surname> <given-names>K</given-names></name>. <article-title>Therapies Targeting Inflammation After Stent Implantation</article-title>.<source>Curr Vasc Pharmacol</source>. <year>2013</year>; <volume>11</volume>: <fpage>399</fpage>–<lpage>406</lpage>. <object-id pub-id-type="pmid">23905635</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nissen</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Wolski</surname> <given-names>K</given-names></name>. <article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title>. <source>N Engl J Med</source>. <year>2007</year>; <volume>356</volume>: <fpage>2457</fpage>–<lpage>2471</lpage>. <object-id pub-id-type="pmid">17517853</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lincoff</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Wolski</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nicholls</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Nissen</surname> <given-names>SE</given-names></name>. <article-title>Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials</article-title>. <source>Jama</source>. <year>2007</year>; <volume>298</volume>: <fpage>1180</fpage>–<lpage>1188</lpage>. <object-id pub-id-type="pmid">17848652</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Henney</surname> <given-names>JE</given-names></name>. <article-title>Withdrawal of Troglitazone and Cisapride</article-title>. <source>Jama</source>. <year>2000</year>; <volume>283</volume>: <fpage>2228</fpage>.</mixed-citation></ref>
<ref id="pone.0155273.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patel</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Walitt</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Lindsay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wilensky</surname> <given-names>RL</given-names></name>. <article-title>Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2011</year>; <volume>4</volume>: <fpage>353</fpage>–<lpage>360</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcin.2010.10.016" xlink:type="simple">10.1016/j.jcin.2010.10.016</ext-link></comment> <object-id pub-id-type="pmid">21435616</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moussa</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Leon</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Baim</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>O'Neill</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Popma</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Buchbinder</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy</article-title>. <source>Circulation</source>. <year>2004</year>; <volume>109</volume>: <fpage>2273</fpage>–<lpage>2278</lpage>. <object-id pub-id-type="pmid">15123524</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kitoga</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pasquet</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Preumont</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Kefer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hermans</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Vanoverschelde</surname> <given-names>JL</given-names></name>, <etal>et al</etal>. <article-title>Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents</article-title>. <source>Diabetes Metab</source>. <year>2008</year>; <volume>34</volume>: <fpage>62</fpage>–<lpage>67</lpage>. <object-id pub-id-type="pmid">18069029</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Ahn</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Ahn</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Bae</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Shim</surname> <given-names>WJ</given-names></name>, <etal>et al</etal>. <article-title>Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes</article-title>. <source>Heart</source>. <year>2006</year>; <volume>92</volume>: <fpage>1119</fpage>–<lpage>1124</lpage>. <object-id pub-id-type="pmid">16449516</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guerra</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Byrne</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Kastrati</surname></name>. <article-title>A Pharmacological inhibition of coronary restenosis: systemic and local approaches</article-title>. <source>Expert Opin Pharmacother</source>. <year>2014</year>; <volume>15</volume>: <fpage>2155</fpage>–<lpage>2171</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14656566.2014.948844" xlink:type="simple">10.1517/14656566.2014.948844</ext-link></comment> <object-id pub-id-type="pmid">25145263</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>Ann Intern Med</source>. <year>2009</year>; <volume>151</volume>: <fpage>264</fpage>–<lpage>269</lpage>, W64. <object-id pub-id-type="pmid">19622511</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref015"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Higgins J, Green S (2010) Cochrane handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration, 2009. Available: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org" xlink:type="simple">www.cochrane-handbook.org</ext-link>.</mixed-citation></ref>
<ref id="pone.0155273.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yeh</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hsieh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>W</given-names></name>. <article-title>Effects of Thiazolidinediones on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After Drug-Eluting Stent Implantation: A Retrospective Cohort Study Using the National Health Insurance Database in Taiwan</article-title>. <source>Clinical Therapeutics</source>. <year>2012</year>; <volume>34</volume>: <fpage>885</fpage>–<lpage>893</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinthera.2012.02.024" xlink:type="simple">10.1016/j.clinthera.2012.02.024</ext-link></comment> <object-id pub-id-type="pmid">22440193</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ozawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Oda</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Oda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hosaka</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kashimura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ozaki</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Improved cardiac function after sirolimus-eluting stent placement in diabetic patients by pioglitazone: Combination therapy with statin</article-title>. <source>Journal of Cardiology</source>. <year>2009</year>; <volume>53</volume>: <fpage>402</fpage>–<lpage>409</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jjcc.2009.01.011" xlink:type="simple">10.1016/j.jjcc.2009.01.011</ext-link></comment> <object-id pub-id-type="pmid">19477383</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takagi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yamamuro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tamita</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Katayama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Morioka</surname> <given-names>S</given-names></name>. <article-title>Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: An intravascular ultrasound study</article-title>. <source>Journal of Cardiology</source>. <year>2005</year>; <volume>45</volume>: <fpage>139</fpage>–<lpage>147</lpage>. <object-id pub-id-type="pmid">15875535</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takagi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Akasaka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yamamuro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Honda</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hozumi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Morioka</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantationIntravascular ultrasound studies</article-title>. <source>Journal of Diabetes and its Complications</source>. <year>2002</year>; <volume>16</volume>: <fpage>50</fpage>–<lpage>55</lpage>. <object-id pub-id-type="pmid">11872367</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>HW</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation</article-title>. <source>Yonsei Med J</source>. <year>2013</year>; <volume>54</volume>: <fpage>1313</fpage>–<lpage>1320</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3349/ymj.2013.54.6.1313" xlink:type="simple">10.3349/ymj.2013.54.6.1313</ext-link></comment> <object-id pub-id-type="pmid">24142633</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahn</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>; <volume>57</volume>: <fpage>E1914</fpage>.</mixed-citation></ref>
<ref id="pone.0155273.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takagi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Okura</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kobayashi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kataoka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Taguchi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Toda</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2009</year>; <volume>2</volume>: <fpage>524</fpage>–<lpage>531</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcin.2009.04.007" xlink:type="simple">10.1016/j.jcin.2009.04.007</ext-link></comment> <object-id pub-id-type="pmid">19539256</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yokoyama</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sutoh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Higuma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Horiuchi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Katoh</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yokota</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance</article-title>. <source>Heart Vessels</source>. <year>2007</year>; <volume>22</volume>: <fpage>146</fpage>–<lpage>151</lpage>. <object-id pub-id-type="pmid">17533517</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nishio</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sakurai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kusuyama</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Shigemitsu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fukui</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kawamura</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2006</year>; <volume>29</volume>: <fpage>101</fpage>–<lpage>106</lpage>. <object-id pub-id-type="pmid">16373904</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takagi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yamamuro</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tamita</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yamabe</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Katayama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mizoguchi</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study</article-title>. <source>Am Heart J</source>. <year>2003</year>; <volume>146</volume>: <fpage>E5</fpage>. <object-id pub-id-type="pmid">12891212</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oremus</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wolfson</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Perrault</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Demers</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Momoli</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Moride</surname> <given-names>Y</given-names></name>. <article-title>Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2001</year>; <volume>12</volume>: <fpage>232</fpage>–<lpage>236</lpage>. <object-id pub-id-type="pmid">11244218</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kornowski</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Tio</surname> <given-names>FO</given-names></name>, <name name-style="western"><surname>Bramwell</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Leon</surname> <given-names>MB</given-names></name>. <article-title>In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>; <volume>31</volume>: <fpage>224</fpage>–<lpage>230</lpage>. <object-id pub-id-type="pmid">9426044</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gilbert</surname> <given-names>RE</given-names></name>. <article-title>Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications</article-title>. <source>Circ J</source>. <year>2013</year>; <volume>77</volume>: <fpage>849</fpage>–<lpage>856</lpage>. <object-id pub-id-type="pmid">23503045</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Delhaye</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Maluenda</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wakabayashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ben-Dor</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Lemesle</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Collins</surname> <given-names>SD</given-names></name>, <etal>et al</etal>. <article-title>Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation</article-title>. <source>Am J Cardiol</source>. <year>2010</year>; <volume>105</volume>: <fpage>826</fpage>–<lpage>832</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2009.10.064" xlink:type="simple">10.1016/j.amjcard.2009.10.064</ext-link></comment> <object-id pub-id-type="pmid">20211326</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Satoh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ogawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Usui</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tagami</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kono</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Uesugi</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect</article-title>. <source>Diabetes Care</source>. <year>2003</year>; <volume>26</volume>: <fpage>2493</fpage>–<lpage>2499</lpage>. <object-id pub-id-type="pmid">12941708</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yki-Järvinen</surname> <given-names>H</given-names></name>. <article-title>Thiazolidinediones</article-title>. <source>N Engl J Med</source>. <year>2004</year>; <volume>351</volume>: <fpage>1106</fpage>–<lpage>1118</lpage>. <object-id pub-id-type="pmid">15356308</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barlaka</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Galatou</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mellidis</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Ravingerova</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lazou</surname> <given-names>A</given-names></name>. <article-title>Role of pleiotropic properties of peroxisome proliferator-activated receptors in the heart: focus on the non-metabolic effects in cardiac protection</article-title>. <source>Cardiovasc Ther</source>. <year>2015</year>.</mixed-citation></ref>
<ref id="pone.0155273.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cheang</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Fang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Tian</surname> <given-names>XY</given-names></name>. <article-title>Pleiotropic effects of peroxisome proliferator-activated receptor gamma and delta in vascular diseases</article-title>. <source>Circ J</source>. <year>2013</year>; <volume>77</volume>: <fpage>2664</fpage>–<lpage>2671</lpage>. <object-id pub-id-type="pmid">24107399</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Cho</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Joo</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>CW</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis</article-title>. <source>Circ J</source>. <year>2015</year>; <volume>79</volume>: <fpage>880</fpage>–<lpage>888</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1253/circj.CJ-14-0964" xlink:type="simple">10.1253/circj.CJ-14-0964</ext-link></comment> <object-id pub-id-type="pmid">25737017</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roiron</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sanchez</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Bouzamondo</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lechat</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Montalescot</surname> <given-names>G</given-names></name>. <article-title>Drug eluting stents: an updated meta-analysis of randomised controlled trials</article-title>. <source>Heart</source>. <year>2006</year>; <volume>92</volume>: <fpage>641</fpage>–<lpage>649</lpage>. <object-id pub-id-type="pmid">16216853</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wood</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Marks</surname> <given-names>AR</given-names></name>. <article-title>Drug-eluting stents</article-title>. <source>Annu Rev Med</source>. <year>2004</year>; <volume>55</volume>: <fpage>169</fpage>–<lpage>178</lpage>. <object-id pub-id-type="pmid">14746515</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YH</given-names></name>, <etal>et al</etal>. <article-title>Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era</article-title>. <source>Am J Cardiol</source>. <year>2005</year>; <volume>96</volume>: <fpage>1389</fpage>–<lpage>1392</lpage>. <object-id pub-id-type="pmid">16275184</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abizaid</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kornowski</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mintz</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Abizaid</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Mehran</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>; <volume>32</volume>: <fpage>584</fpage>–<lpage>589</lpage>. <object-id pub-id-type="pmid">9741497</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldberg</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Kendall</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Deeg</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Buse</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Zagar</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Pinaire</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia</article-title>. <source>Diabetes Care</source>. <year>2005</year>; <volume>28</volume>: <fpage>1547</fpage>–<lpage>1554</lpage>. <object-id pub-id-type="pmid">15983299</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nissen</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Nicholls</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Wolski</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nesto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kupfer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Perez</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial</article-title>. <source>Jama</source>. <year>2008</year>; <volume>299</volume>: <fpage>1561</fpage>–<lpage>1573</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.299.13.1561" xlink:type="simple">10.1001/jama.299.13.1561</ext-link></comment> <object-id pub-id-type="pmid">18378631</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mizoguchi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tahara</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tahara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nitta</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kodama</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Oba</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2011</year>; <volume>4</volume>: <fpage>1110</fpage>–<lpage>1118</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcmg.2011.08.007" xlink:type="simple">10.1016/j.jcmg.2011.08.007</ext-link></comment> <object-id pub-id-type="pmid">21999871</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nitta</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tahara</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Tahara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Honda</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kodama</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Mizoguchi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2013</year>; <volume>6</volume>: <fpage>1172</fpage>–<lpage>1182</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jcmg.2013.09.004" xlink:type="simple">10.1016/j.jcmg.2013.09.004</ext-link></comment> <object-id pub-id-type="pmid">24229770</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saremi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schwenke</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Buchanan</surname> <given-names>TA</given-names></name>, <name name-style="western"><surname>Hodis</surname> <given-names>HN</given-names></name>, <name name-style="western"><surname>Mack</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Banerji</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2013</year>; <volume>33</volume>: <fpage>393</fpage>–<lpage>399</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/ATVBAHA.112.300346" xlink:type="simple">10.1161/ATVBAHA.112.300346</ext-link></comment> <object-id pub-id-type="pmid">23175674</object-id></mixed-citation></ref>
<ref id="pone.0155273.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Erdmann</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Harding</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Perez</surname> <given-names>A</given-names></name>. <article-title>Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>: <fpage>266</fpage>–<lpage>273</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/dom.12608" xlink:type="simple">10.1111/dom.12608</ext-link></comment> <object-id pub-id-type="pmid">26592506</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>